Skip to main content

Table 1 Published datasets included in the meta-analysis

From: A functional Notchsurvivin gene signature in basal breast cancer

Study

n

Median age (years)

Microarray

Tumor size

Lymph nodes (LN)

Treatment

Stage/grade

Chin and colleagues [55]

118

55.3 (SD = 14.3)

Affymetrix

2.6 cm (SD = 1.3)

67 LN-positive, 51 LN-negative

60% tamoxifen, 52% adjuvant chemotherapy, 51% radiation

26 stage 1, 70 stage 2, 14 stage 3, 5 stage 4; 10 grade 1, 42 grade 2, 61 grade 3; 5 unknown

Desmedt and colleagues [56]

198

47 (all < 61)

Affymetrix

< 5 cm

Node-negative

 

T1–T2

Ginestier and colleagues [57]

55

 

Affymetrix

  

19 amplified for 20q13, 36 unamplified for 20q13

Consecutive cases, unilateral localized invasive breast cancer

Hess and colleagues [58]

133

Training set, 52 (range 29 to 79); validation set, 50 (range 28 to 73)

Affymetrix

  

Preoperative weekly paclitaxel and fluorouracil–doxorubicin–cyclophosphamide chemotherapy

Stage I, stage II, stage III

Ivshina and colleagues [59]

249 (Uppsala cohort)

62.3

Affymetrix

2.9 cm

35% node-positive

30.3% endocrine therapy, 10.7% chemotherapy, 1.7% combination therapy, 58.8% no systemic therapy

68 grade 1, 126 grade 2, 55 grade 3

Miller and colleagues [60]

251

62.1 (SD = 13.9)

Affymetrix

22.4 mm (SD = 12.5)

84/253 LN metastasis, 160 node-negative, 9 unknown node status

143 no adjuvant therapy; others with systemic adjuvant therapy, and/or chemotherapy

 

Minn and colleagues [61]

82

55.8 (SD = 13.5)

Affymetrix

3.68 cm (SD = 1.77 cm)

Average 3.5 (SD = 5.98) axillary LN

Adjuvant chemotherapy and/or hormonal therapy

 

Richardson and colleagues [62]

39

 

Affymetrix

    

Saal and colleagues [37]

105

61 (range 26 to 77)

Non-Affymetrix

27 mm (range 2 to 50 mm)

65 (62%) LN-positive

Treated uniformly with 2 years of adjuvant tamoxifen

Stage II, primary breast cancer

Sotiriou and colleagues [63]

119 (KJ125 dataset)

45% < 50, 55% > 50

Affymetrix

61% < 2 cm, 39% > 2 cm

LN-negative

No adjuvant systemic therapy

34 grade 1, 46 grade 2, 28 grade 3, 17 not available

Turashvili and colleagues [32]

10

 

Affymetrix

   

3 grade I, 5 grade II, 2 grade III

van de Vijver and colleagues [64]

295

< 52

Non-Affymetrix

< 5 cm

151 LN-negative, 144 LN-positive

Modified radical mastectomy or breast-conserving surgery

Stage I or stage II breast cancer

Wang and colleagues [65]

286

54 (SD = 12)

Affymetrix

 

LN-negative

No adjuvant treatment

 

Yu and colleagues [38]

96 (only 68 with Notch-1 and survivin data)

55 (SD = 10.9)

Affymetrix

37.7 mm (SD = 17.9)

37.5% LN-negative

 

2 unknown grade, 5 grade I, 26 grade II, 63 grade III

Zhao and colleagues [36]

59 (35 intraductal carcinoma, 17 intralobular carcinoma; three from each with unknown ER status)

Ductal, 53 (SD = 15.5); lobular, 63.5 (SD = 14.0)

Non-Affymetrix

 

Ductal, 16 LN-positive, 16 LN-negative, 3 LN unknown; lobular, 7 LN-positive, 7 LN-negative, 4 LN unknown

 

Ductal, 5 grade I, 19 grade II, 11 grade III; lobular, 17 grade II, 1 grade I

  1. Sixteen datasets derived from an unbiased search of human breast cancer microarrays on Oncomine were identified that matched the study criteria.